Lumos Pharma Inc. traded at $2.69 this Tuesday April 9th, increasing $0.04 or 1.51 percent since the previous trading session. Looking back, over the last four weeks, Lumos Pharma gained 11.80 percent. Over the last 12 months, its price fell by 17.99 percent. Looking ahead, we forecast Lumos Pharma Inc. to be priced at 2.61 by the end of this quarter and at 2.38 in one year, according to Trading Economics global macro models projections and analysts expectations.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.